CardioCovidV1, Main, Exploration, bibRecordById, pubmed:32367746

ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.

Identifieur interne : 000397 ( Main/Exploration ); précédent : 000396; suivant : 000398

ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.

Auteurs : Andrew M. South [États-Unis] ; Tammy M. Brady ; Joseph T. Flynn

Source :

Hypertension (Dallas, Tex. : 1979) [ 1524-4563 ] ; 2020.

RBID : pubmed:32367746

Descripteurs français

KwdFr :
- Antagonistes des récepteurs aux angiotensines (pharmacologie), Betacoronavirus (physiologie), Comorbidité (MeSH), Enfant (MeSH), Humains (MeSH), Hypertension artérielle (métabolisme), Hypertension artérielle (traitement médicamenteux), Hypertension artérielle (épidémiologie), Infections à coronavirus (métabolisme), Infections à coronavirus (virologie), Infections à coronavirus (épidémiologie), Inhibiteurs de l'enzyme de conversion de l'angiotensine (pharmacologie), Pandémies (MeSH), Peptidyl-Dipeptidase A (métabolisme), Pneumopathie virale (métabolisme), Pneumopathie virale (virologie), Pneumopathie virale (épidémiologie), Système rénine-angiotensine (effets des médicaments et des substances chimiques), Système rénine-angiotensine (physiologie).
MESH :
- effets des médicaments et des substances chimiques : Système rénine-angiotensine.
- métabolisme : Hypertension artérielle, Infections à coronavirus, Peptidyl-Dipeptidase A, Pneumopathie virale.
- pharmacologie : Antagonistes des récepteurs aux angiotensines, Inhibiteurs de l'enzyme de conversion de l'angiotensine.
- physiologie : Betacoronavirus, Système rénine-angiotensine.
- traitement médicamenteux : Hypertension artérielle.
- virologie : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Hypertension artérielle, Infections à coronavirus, Pneumopathie virale.
- Comorbidité, Enfant, Humains, Pandémies.

English descriptors

KwdEn :
- Angiotensin Receptor Antagonists (pharmacology), Angiotensin-Converting Enzyme Inhibitors (pharmacology), Betacoronavirus (physiology), Child (MeSH), Comorbidity (MeSH), Coronavirus Infections (epidemiology), Coronavirus Infections (metabolism), Coronavirus Infections (virology), Humans (MeSH), Hypertension (drug therapy), Hypertension (epidemiology), Hypertension (metabolism), Pandemics (MeSH), Peptidyl-Dipeptidase A (metabolism), Pneumonia, Viral (epidemiology), Pneumonia, Viral (metabolism), Pneumonia, Viral (virology), Renin-Angiotensin System (drug effects), Renin-Angiotensin System (physiology).
MESH :
- chemical , metabolism : Peptidyl-Dipeptidase A.
- chemical , pharmacology : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors.
- drug effects : Renin-Angiotensin System.
- drug therapy : Hypertension.
- epidemiology : Coronavirus Infections, Hypertension, Pneumonia, Viral.
- metabolism : Coronavirus Infections, Hypertension, Pneumonia, Viral.
- physiology : Betacoronavirus, Renin-Angiotensin System.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Child, Comorbidity, Humans, Pandemics.

Abstract

Potential but unconfirmed risk factors for coronavirus disease 2019 (COVID-19) in adults and children may include hypertension, cardiovascular disease, and chronic kidney disease, as well as the medications commonly prescribed for these conditions, ACE (angiotensin-converting enzyme) inhibitors, and Ang II (angiotensin II) receptor blockers. Coronavirus binding to ACE2 (angiotensin-converting enzyme 2), a crucial component of the renin-angiotensin-aldosterone system, underlies much of this concern. Children are uniquely impacted by the coronavirus, but the reasons are unclear. This review will highlight the relationship of COVID-19 with hypertension, use of ACE inhibitors and Ang II receptor blockers, and lifetime risk of cardiovascular disease from the pediatric perspective. We briefly summarize the renin-angiotensin-aldosterone system and comprehensively review the literature pertaining to the ACE 2/Ang-(1-7) pathway in children and the clinical evidence for how ACE inhibitors and Ang II receptor blockers affect this important pathway. Given the importance of the ACE 2/Ang-(1-7) pathway and the potential differences between adults and children, it is crucial that children are included in coronavirus-related research, as this may shed light on potential mechanisms for why children are at decreased risk of severe COVID-19.

DOI: 10.1161/HYPERTENSIONAHA.120.15291
PubMed: 32367746
PubMed Central: PMC7289676

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000314
to stream Main, to step Curation: 000314

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.</title>
<author><name sortKey="South, Andrew M" sort="South, Andrew M" uniqKey="South A" first="Andrew M" last="South">Andrew M. South</name>
<affiliation><nlm:affiliation>From the Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine and Brenner Children's Hospital (A.M.S.).</nlm:affiliation>
<wicri:noCountry code="subField">Wake Forest School of Medicine and Brenner Children's Hospital (A.M.S.).</wicri:noCountry>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery-Hypertension and Vascular Research (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>Department of Surgery-Hypertension and Vascular Research (A.M.S.), Wake Forest School of Medicine, Winston Salem</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Division of Public Health Sciences, Department of Epidemiology and Prevention (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>Division of Public Health Sciences, Department of Epidemiology and Prevention (A.M.S.), Wake Forest School of Medicine, Winston Salem</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Cardiovascular Sciences Center (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>Cardiovascular Sciences Center (A.M.S.), Wake Forest School of Medicine, Winston Salem</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Brady, Tammy M" sort="Brady, Tammy M" uniqKey="Brady T" first="Tammy M" last="Brady">Tammy M. Brady</name>
<affiliation><nlm:affiliation>Division of Nephrology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD (T.M.B.).</nlm:affiliation>
<wicri:noCountry code="subField">MD (T.M.B.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Flynn, Joseph T" sort="Flynn, Joseph T" uniqKey="Flynn J" first="Joseph T" last="Flynn">Joseph T. Flynn</name>
<affiliation><nlm:affiliation>Department of Pediatrics, University of Washington School of Medicine and Division of Nephrology, Seattle Children's Hospital (J.T.F.).</nlm:affiliation>
<wicri:noCountry code="subField">Seattle Children's Hospital (J.T.F.).</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32367746</idno>
<idno type="pmid">32367746</idno>
<idno type="doi">10.1161/HYPERTENSIONAHA.120.15291</idno>
<idno type="pmc">PMC7289676</idno>
<idno type="wicri:Area/Main/Corpus">000314</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000314</idno>
<idno type="wicri:Area/Main/Curation">000314</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000314</idno>
<idno type="wicri:Area/Main/Exploration">000314</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.</title>
<author><name sortKey="South, Andrew M" sort="South, Andrew M" uniqKey="South A" first="Andrew M" last="South">Andrew M. South</name>
<affiliation><nlm:affiliation>From the Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine and Brenner Children's Hospital (A.M.S.).</nlm:affiliation>
<wicri:noCountry code="subField">Wake Forest School of Medicine and Brenner Children's Hospital (A.M.S.).</wicri:noCountry>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery-Hypertension and Vascular Research (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>Department of Surgery-Hypertension and Vascular Research (A.M.S.), Wake Forest School of Medicine, Winston Salem</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Division of Public Health Sciences, Department of Epidemiology and Prevention (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>Division of Public Health Sciences, Department of Epidemiology and Prevention (A.M.S.), Wake Forest School of Medicine, Winston Salem</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Cardiovascular Sciences Center (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>Cardiovascular Sciences Center (A.M.S.), Wake Forest School of Medicine, Winston Salem</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Brady, Tammy M" sort="Brady, Tammy M" uniqKey="Brady T" first="Tammy M" last="Brady">Tammy M. Brady</name>
<affiliation><nlm:affiliation>Division of Nephrology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD (T.M.B.).</nlm:affiliation>
<wicri:noCountry code="subField">MD (T.M.B.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Flynn, Joseph T" sort="Flynn, Joseph T" uniqKey="Flynn J" first="Joseph T" last="Flynn">Joseph T. Flynn</name>
<affiliation><nlm:affiliation>Department of Pediatrics, University of Washington School of Medicine and Division of Nephrology, Seattle Children's Hospital (J.T.F.).</nlm:affiliation>
<wicri:noCountry code="subField">Seattle Children's Hospital (J.T.F.).</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series><title level="j">Hypertension (Dallas, Tex. : 1979)</title>
<idno type="eISSN">1524-4563</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin Receptor Antagonists (pharmacology)</term>
<term>Angiotensin-Converting Enzyme Inhibitors (pharmacology)</term>
<term>Betacoronavirus (physiology)</term>
<term>Child (MeSH)</term>
<term>Comorbidity (MeSH)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (metabolism)</term>
<term>Coronavirus Infections (virology)</term>
<term>Humans (MeSH)</term>
<term>Hypertension (drug therapy)</term>
<term>Hypertension (epidemiology)</term>
<term>Hypertension (metabolism)</term>
<term>Pandemics (MeSH)</term>
<term>Peptidyl-Dipeptidase A (metabolism)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (metabolism)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Renin-Angiotensin System (drug effects)</term>
<term>Renin-Angiotensin System (physiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines (pharmacologie)</term>
<term>Betacoronavirus (physiologie)</term>
<term>Comorbidité (MeSH)</term>
<term>Enfant (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hypertension artérielle (métabolisme)</term>
<term>Hypertension artérielle (traitement médicamenteux)</term>
<term>Hypertension artérielle (épidémiologie)</term>
<term>Infections à coronavirus (métabolisme)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (pharmacologie)</term>
<term>Pandémies (MeSH)</term>
<term>Peptidyl-Dipeptidase A (métabolisme)</term>
<term>Pneumopathie virale (métabolisme)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Système rénine-angiotensine (effets des médicaments et des substances chimiques)</term>
<term>Système rénine-angiotensine (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Peptidyl-Dipeptidase A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Angiotensin Receptor Antagonists</term>
<term>Angiotensin-Converting Enzyme Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Renin-Angiotensin System</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypertension</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Système rénine-angiotensine</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Betacoronavirus</term>
<term>Système rénine-angiotensine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term>
<term>Renin-Angiotensin System</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hypertension artérielle</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Child</term>
<term>Comorbidity</term>
<term>Humans</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Comorbidité</term>
<term>Enfant</term>
<term>Humains</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Potential but unconfirmed risk factors for coronavirus disease 2019 (COVID-19) in adults and children may include hypertension, cardiovascular disease, and chronic kidney disease, as well as the medications commonly prescribed for these conditions, ACE (angiotensin-converting enzyme) inhibitors, and Ang II (angiotensin II) receptor blockers. Coronavirus binding to ACE2 (angiotensin-converting enzyme 2), a crucial component of the renin-angiotensin-aldosterone system, underlies much of this concern. Children are uniquely impacted by the coronavirus, but the reasons are unclear. This review will highlight the relationship of COVID-19 with hypertension, use of ACE inhibitors and Ang II receptor blockers, and lifetime risk of cardiovascular disease from the pediatric perspective. We briefly summarize the renin-angiotensin-aldosterone system and comprehensively review the literature pertaining to the ACE 2/Ang-(1-7) pathway in children and the clinical evidence for how ACE inhibitors and Ang II receptor blockers affect this important pathway. Given the importance of the ACE 2/Ang-(1-7) pathway and the potential differences between adults and children, it is crucial that children are included in coronavirus-related research, as this may shed light on potential mechanisms for why children are at decreased risk of severe COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32367746</PMID>
<DateCompleted><Year>2020</Year>
<Month>06</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>06</Month>
<Day>22</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4563</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>76</Volume>
<Issue>1</Issue>
<PubDate><Year>2020</Year>
<Month>07</Month>
</PubDate>
</JournalIssue>
<Title>Hypertension (Dallas, Tex. : 1979)</Title>
<ISOAbbreviation>Hypertension</ISOAbbreviation>
</Journal>
<ArticleTitle>ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.</ArticleTitle>
<Pagination><MedlinePgn>16-22</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1161/HYPERTENSIONAHA.120.15291</ELocationID>
<Abstract><AbstractText>Potential but unconfirmed risk factors for coronavirus disease 2019 (COVID-19) in adults and children may include hypertension, cardiovascular disease, and chronic kidney disease, as well as the medications commonly prescribed for these conditions, ACE (angiotensin-converting enzyme) inhibitors, and Ang II (angiotensin II) receptor blockers. Coronavirus binding to ACE2 (angiotensin-converting enzyme 2), a crucial component of the renin-angiotensin-aldosterone system, underlies much of this concern. Children are uniquely impacted by the coronavirus, but the reasons are unclear. This review will highlight the relationship of COVID-19 with hypertension, use of ACE inhibitors and Ang II receptor blockers, and lifetime risk of cardiovascular disease from the pediatric perspective. We briefly summarize the renin-angiotensin-aldosterone system and comprehensively review the literature pertaining to the ACE 2/Ang-(1-7) pathway in children and the clinical evidence for how ACE inhibitors and Ang II receptor blockers affect this important pathway. Given the importance of the ACE 2/Ang-(1-7) pathway and the potential differences between adults and children, it is crucial that children are included in coronavirus-related research, as this may shed light on potential mechanisms for why children are at decreased risk of severe COVID-19.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>South</LastName>
<ForeName>Andrew M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>From the Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine and Brenner Children's Hospital (A.M.S.).</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Surgery-Hypertension and Vascular Research (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Epidemiology and Prevention (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Cardiovascular Sciences Center (A.M.S.), Wake Forest School of Medicine, Winston Salem, NC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brady</LastName>
<ForeName>Tammy M</ForeName>
<Initials>TM</Initials>
<AffiliationInfo><Affiliation>Division of Nephrology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD (T.M.B.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Flynn</LastName>
<ForeName>Joseph T</ForeName>
<Initials>JT</Initials>
<AffiliationInfo><Affiliation>Department of Pediatrics, University of Washington School of Medicine and Division of Nephrology, Seattle Children's Hospital (J.T.F.).</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>L40 HL148910</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 HL146818</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Hypertension</MedlineTA>
<NlmUniqueID>7906255</NlmUniqueID>
<ISSNLinking>0194-911X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber>
<NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012084" MajorTopicYN="N">Renin-Angiotensin System</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year>
<Month>07</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32367746</ArticleId>
<ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15291</ArticleId>
<ArticleId IdType="pmc">PMC7289676</ArticleId>
<ArticleId IdType="mid">NIHMS1591731</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>JAMA Pediatr. 2019 Oct 7;:1-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31589252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Nephrol. 2020 Jun;16(6):305-307</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32246101</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Hypertens (Greenwich). 2017 Jan;19(1):90-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27481566</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Hypertens. 2015 Jan;28(1):15-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24842388</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2007 Jan;49(1):185-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17116756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Res. 2006 Dec;60(6):734-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17065573</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 23;382(17):1653-1659</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227760</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Mar 13;367(6483):1260-1263</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32075877</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Nephrol. 2013;38(5):355-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24158104</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res. 2016 May;107:154-162</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26995300</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Res. 2005 Oct 28;97(9):946-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16179584</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vascul Pharmacol. 2019 Apr;115:13-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30707954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Pediatr. 2020 Apr 8;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32267485</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Coll Cardiol. 2008 Aug 26;52(9):750-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18718423</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Peptides. 2017 Apr;90:10-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28192151</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intensive Care. 2019 May 14;9(1):55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31089908</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Jul;35(7):625-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17961427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2019 Mar 26;139(13):e603-e634</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30798614</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Heart Fail Rev. 2019 Sep;24(5):709-723</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31104255</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32271728</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Pharmacol. 2016 May;173(10):1618-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26895462</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertens Res. 2013 Jan;36(1):5-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23076408</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Pharmacol. 1994 Jan;111(1):1-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8012686</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 6;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32250385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Heart Fail. 2020 Jun 2;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32485082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2004 May;43(5):970-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15007027</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 23;382(17):1663-1665</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187458</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Nephrol. 2012 Mar;27(3):363-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21713524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pediatr. 2004 Jul;145(1):93-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15238914</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2015 Nov;66(5):920-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26324508</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2020 Mar 17;94(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31996437</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1084-H1090</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32228252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2020 Jun;75(6):1382-1385</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32208987</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Res. 2020 Apr 15;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32293003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Exp Med Biol. 2017;956:307-325</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27873228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240123</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Invest. 2009 Jul;39(7):618-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19453650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Sci (Lond). 2019 Jan 8;133(1):55-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30622158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Jul 7;436(7047):112-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16001071</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Endocrinol (Lausanne). 2014 Jan 09;4:201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24409169</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hypertens. 2018 Oct;36(10):2092-2101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29846325</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2016 Jan 27;6:19840</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26813885</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertens Res. 2019 Oct;42(10):1631-1643</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31160699</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2012 Jan;129(1):e1-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22144698</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin J Am Soc Nephrol. 2020 May 7;15(5):714-716</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32220930</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med Exp. 2015 Dec;3(1):44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26215809</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2005 May 24;111(20):2605-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15897343</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Renin Angiotensin Aldosterone Syst. 2016 Jul 18;17(3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27432541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Kidney Dis. 2008 Apr;51(4):613-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18371537</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Feb 28;368:m810</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32111649</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Med Genet. 2013 Nov 05;14:117</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24191856</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci China Life Sci. 2020 Mar;63(3):364-374</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32048163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Exp Mol Pathol. 2020 Apr;113:104350</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31805278</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Nephrol. 2012 Oct;27(10):1835-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21947887</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Nephrol. 2017 Sep;32(9):1585-1594</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28411317</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2005 Aug;11(8):875-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16007097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Heart Circ Physiol. 2016 Jan 15;310(2):H137-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26475588</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2008 Jul;295(1):L178-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18441099</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):e21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2018 Oct;72(4):918-928</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30354721</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Card Fail. 2009 Sep;15(7):565-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19700132</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2004 Dec;204(5):587-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15538735</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
</region>
</list>
<tree><noCountry><name sortKey="Brady, Tammy M" sort="Brady, Tammy M" uniqKey="Brady T" first="Tammy M" last="Brady">Tammy M. Brady</name>
<name sortKey="Flynn, Joseph T" sort="Flynn, Joseph T" uniqKey="Flynn J" first="Joseph T" last="Flynn">Joseph T. Flynn</name>
</noCountry>
<country name="États-Unis"><region name="Caroline du Nord"><name sortKey="South, Andrew M" sort="South, Andrew M" uniqKey="South A" first="Andrew M" last="South">Andrew M. South</name>
</region>
<name sortKey="South, Andrew M" sort="South, Andrew M" uniqKey="South A" first="Andrew M" last="South">Andrew M. South</name>
<name sortKey="South, Andrew M" sort="South, Andrew M" uniqKey="South A" first="Andrew M" last="South">Andrew M. South</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000397 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000397 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CardioCovidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32367746
   |texte=   ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32367746" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CardioCovidV1

This area was generated with Dilib version V0.6.35.
Data generation: Tue Aug 4 15:08:30 2020. Site generation: Wed Jan 27 11:23:02 2021

	Serveur d'exploration Covid et maladies cardiovasculaires
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Covid et maladies cardiovasculaires

ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.

ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki